(Q83979395)

English

A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy

scientific article published on 29 November 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Hyun Cheol Chung

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Hei Cheul Jeung

1

object named as

Hei-Cheul Jeung

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

7

object named as

Jae Kyung Roh

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Chong Kun Cheon

3

object named as

Chong Kun Im

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

6

object named as

Woo Ick Yang

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

29 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

117

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

2050-2057

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with recurrent or metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

SPARC is associated with gastric cancer progression and poor survival of patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Interaction between SPARC and tubulin in Xenopus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunohistochemical detection of the X-linked inhibitor of apoptosis protein (XIAP) in cervical squamous intraepithelial neoplasia and squamous carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Cutaneous Hand and Foot Toxicity Associated With Cancer Chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Review of second-line chemotherapy for advanced gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25729

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25729

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523716%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83979395&oldid=2073528381"